2. Signaling Pathways
  3. Immunology/Inflammation
  4. Toll-like Receptor (TLR)
  5. TLR8 Isoform
  6. TLR8 Antagonist

TLR8 Antagonist

TLR8 Antagonists (6):

Cat. No. Product Name Effect Purity
  • HY-178037
    TLR9 antagonist 1
    		Antagonist
    TLR9 antagonist 1 (Compound 38) is a selective TLR9 antagonist with an IC50 of 0.1  nM for hTLR9 over hTLR2/4/5/7/8. TLR9 antagonist 1 exacerbates disease symptoms with increased anti-dsDNA and anti-Sm levels in systemic lupus erythematosus (SLE) mouse models. TLR9 antagonist 1 can be used for inflammatory and immune diseases like lupus and arthritis research.
  • HY-112667
    CU-CPT-9a
    		Antagonist 99.74%
    CU-CPT-9a is a specific TLR8 antagonist, with an IC50 of 0.5 nM.
  • HY-112050
    CU-CPT-8m
    		Antagonist 99.98%
    CU-CPT-8m is a specific TLR8 antagonist, with an IC50 of 67 nM.
  • HY-131945
    CU-115
    		Antagonist 99.63%
    CU-115 is a potent TLR8 antagonist (IC50=1.04 µM), and shows selective for TLR8 over TLR7 (IC50=>50 µM). CU-115 decreases TNF-α and IL-1β production activated by R-848 in THP-1 cells.
  • HY-112051
    CU-CPT9b
    		Antagonist 99.03%
    CU-CPT9b is a specific TLR8 antagonist, with an IC50 of 0.7 nM. CU-CPT9b shows high binding affinity towards TLR8 with a Kd of 21 nM.
  • HY-175782
    SMU-R39
    		Antagonist
    SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis.